glp-1 효능 '위고비' 잡는 국내 제약사 비만 신약 출시 앞당긴다 < 글로벌·바이오 < 제약산업 < 기사본문 큐시락토, 경구용 GLP-1 비만치료제 임상2상

J.et al (2018)

The effect is temporary, and the increased side effect risk outweighs any marginal benefit

In the USA, the importance of this cereal ranks third following wheat and corn, and it ranks fourth globally

It is the first GLP-1 receptor agonist tablet for weight-loss to be approved by the Medicines and Healthcare products Regulatory Agency (MHRA), making the UK the third country to authorise the pills, behind the US and the United Arab Emirates

World Health Organization (2016) Diabetes Fact Sheet

Positioning in guidelines In the NICE NG28 guideline, 3 the DPP-4 inhibitors may be used first-line when metformin is contraindicated or not tolerated